

Maite Alvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5253038/publications.pdf>

Version: 2024-02-01

69
papers

1,801
citations

361413

20
h-index

302126

39
g-index

71
all docs

71
docs citations

71
times ranked

2937
citing authors

#	ARTICLE	IF	CITATIONS
1	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. <i>Nature</i> , 2019, 569, 428-432.	27.8	313
2	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 558-576.	27.6	202
3	Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2017, 8, 465.	4.8	162
4	CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells. <i>Blood</i> , 2014, 124, 3320-3328.	1.4	96
5	TNF- β priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. <i>Blood</i> , 2016, 128, 866-871.	1.4	86
6	T cells expressing chimeric antigen receptor promote immune tolerance. <i>JCI Insight</i> , 2017, 2, .	5.0	68
7	Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. <i>Nature Communications</i> , 2017, 8, 15068.	12.8	63
8	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
9	Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway. <i>JCI Insight</i> , 2019, 4, .	5.0	57
10	Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. <i>Blood</i> , 2012, 119, 1590-1598.	1.4	45
11	Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. <i>Blood</i> , 2011, 117, 7032-7041.	1.4	44
12	DR3 signaling modulates the function of Foxp3+ regulatory T cells and the severity of acute graft-versus-host disease. <i>Blood</i> , 2016, 128, 2846-2858.	1.4	43
13	Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell-Mediated Antitumor Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1088-1099.	2.0	42
14	Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 347-355.	0.8	42
15	Increased Antitumor Effects Using IL-2 with Anti-TGF- β 2 Reveals Competition between Mouse NK and CD8 T Cells. <i>Journal of Immunology</i> , 2014, 193, 1709-1716.	0.8	39
16	Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7401-7406.	7.1	38
17	Differential Interleukin-8 thresholds for chemotaxis and netosis in human neutrophils. <i>European Journal of Immunology</i> , 2021, 51, 2274-2280.	2.9	32
18	Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion. <i>Frontiers in Immunology</i> , 2020, 11, 7.	4.8	29

#	ARTICLE	IF	CITATIONS
19	Repurposing the yellow fever vaccine for intratumoral immunotherapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e10375.	6.9	28
20	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. <i>Theranostics</i> , 2020, 10, 4481-4489.	10.0	24
21	Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. <i>Clinical Cancer Research</i> , 2021, 27, 6054-6064.	7.0	23
22	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
23	Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. <i>Blood</i> , 2013, 122, 1518-1521.	1.4	22
24	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. <i>Nature Communications</i> , 2021, 12, 7296.	12.8	22
25	NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. <i>Stem Cells International</i> , 2016, 2016, 1-11.	2.5	21
26	Mouse host unlicensed NK cells promote donor allogeneic bone marrow engraftment. <i>Blood</i> , 2016, 127, 1202-1205.	1.4	19
27	Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. <i>Cell Stress</i> , 2019, 3, 236-239.	3.2	17
28	Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1624.	4.8	16
29	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNF $\hat{\pm}$, and IL-1 $\hat{\beta}$. <i>Cancer Discovery</i> , 2022, 12, 2140-2157.	9.4	16
30	Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1754-1764.	2.0	12
31	Invariant natural killer T-cell subsets have diverse graft-versus-host-disease“preventing and antitumor effects. <i>Blood</i> , 2021, 138, 858-870.	1.4	11
32	Statins act as transient type I interferon inhibitors to enable the antitumor activity of modified vaccinia Ankara viral vectors. , 2021, 9, e001587.		10
33	Contrasting Effects of Anti-Ly49A Due to MHC Class IcisBinding on NK Cell“Mediated Allogeneic Bone Marrow Cell Resistance. <i>Journal of Immunology</i> , 2013, 191, 688-698.	0.8	8
34	TNFR2 signaling modulates immunity after allogeneic hematopoietic cell transplantation. <i>Cytokine and Growth Factor Reviews</i> , 2019, 47, 54-61.	7.2	8
35	IL-2 and Anti-TGF- $\hat{\beta}$ Promote NK Cell Reconstitution and Anti-tumor Effects after Syngeneic Hematopoietic Stem Cell Transplantation. <i>Cancers</i> , 2020, 12, 3189.	3.7	8
36	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8

#	ARTICLE	IF	CITATIONS
37	Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 614250.	4.8	5
38	Modulation of intratumoural myeloid cells, the hallmark of the anti-tumour efficacy induced by a triple combination: tumour-associated peptide, TLR-3 ligand and \pm -PD-1. <i>British Journal of Cancer</i> , 2021, 124, 1275-1285.	6.4	5
39	Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming. <i>Blood</i> , 2019, 134, 867-867.	1.4	5
40	Rapid isolation and enrichment of mouse NK cells for experimental purposes. <i>Methods in Enzymology</i> , 2020, 631, 257-275.	1.0	4
41	Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 65-122.	3.2	4
42	TNF-Alpha Priming Enhances CD4+ FoxP3+ Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment. <i>Blood</i> , 2015, 126, 1885-1885.	1.4	3
43	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3
44	CD4+ Invariant Natural Killer T Cells Protect from Acute Graft-Versus-Host Disease Lethality through a Dramatic Expansion of Donor-Derived CD4+FoxP3+ Regulatory T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S23.	2.0	2
45	IL-2 Plus IL-15 Leads to Enhanced Ex Vivo Expansion of Human Invariant Natural Killer T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S208-S209.	2.0	2
46	CD4+FoxP3+ Regulatory T Cells Promote B Cell Differentiation and Induce Tolerance to Bone Marrow Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S71-S72.	2.0	1
47	On-Orbit measurements of TID and Dose Rate from two RADFETs on board NANOSAT-1B satellite. , 2016, , .		1
48	TNF-Alpha Priming Enhances CD4+FoxP3+ Regulatory T Cell Suppressive Function in GVHD Prevention and Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S144-S145.	2.0	1
49	Scavenger Receptor Class B Type I is Required for 25 μ Hydroxycholecalciferol Cellular Uptake and Signaling in Myeloid Cells. <i>Molecular Nutrition and Food Research</i> , 2020, 64, e1901213.	3.3	1
50	Premortem Tumor Stress in Radioimmunotherapy. <i>Trends in Cancer</i> , 2020, 6, 173-174.	7.4	1
51	Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S42.	2.0	1
52	Activation Status Dictates the Function of Unlicensed Natural Killer Cells. <i>Blood Advances</i> , 2021, 5, 4219-4232.	5.2	1
53	Donor Requirements For CD4+CD25+FoxP3+ Regulatory T Cells Capable Of Suppressing CD4+ and CD8+ Conventional T Cell Proliferation and Graft Versus Host Disease. <i>Blood</i> , 2013, 122, 4484-4484.	1.4	1
54	Abstract 1698: Cellular cytotoxicity is a form of immunogenic cell death. <i>Cancer Research</i> , 2020, 80, 1698-1698.	0.9	1

#	ARTICLE	IF	CITATIONS
55	Natural killer cells in graft-versus-host disease and graft-versus-leukemia. , 2013, , 327-356.		0
56	Impact of Donor T Cells on NK Cell Development after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, S149-S150.	2.0	0
57	Treatment of Donors with Death Receptor 3 Agonistic Fusion Protein TL1A-Ig (with and Without Low) Tj ETQq1 1 0.784314 rgBT /Ove Disease. Biology of Blood and Marrow Transplantation, 2018, 24, S191-S192.	2.0	0
58	Abstract 1691: CD137 (4-1BB) costimulation of CD8 T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. , 2021, , .		0
59	Agonistic Anti-DR3 Antibody Expands Treg and Reduces Experimental Acute Graft-Versus-Host Disease. Blood, 2013, 122, 135-135.	1.4	0
60	CD4+ Invariant Natural Killer T Cells Require NKG2D To Protect From Lethal Acute Graft-Versus-Host Disease. Blood, 2013, 122, 898-898.	1.4	0
61	Adoptive Transfer Of Ex Vivo "Educated" CD4+CD25+FoxP3+ Regulatory T Cells Effectively Treats Acute Graft Versus Host Disease Preserving Graft Versus Tumor Effect. Blood, 2013, 122, 4485-4485.	1.4	0
62	Activation of DR3 Signaling Expands Recipient Derived Regulatory T Cells and Enhances Donor Immune Reconstitution Derived from Allogeneic Hematopoietic Stem Cells. Blood, 2014, 124, 1087-1087.	1.4	0
63	Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation. Blood, 2015, 126, 1876-1876.	1.4	0
64	Foxp3+ regulatory T Cells Maintain Bone Marrow Microenvironment for B Cell Differentiation from Hematopoietic Stem Cells. Blood, 2016, 128, 431-431.	1.4	0
65	DR3 Signaling Modulates the Function of Foxp3+ regulatory T Cells and the Severity of Acute Graft and Host Disease. Blood, 2016, 128, 2148-2148.	1.4	0
66	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
67	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0
68	Abstract 1474: Repurposing the yellow fever vaccine for intratumoral immunotherapy. , 2019, , .		0
69	Abstract 2331: Intratumor adoptive transfer of IL-12 mRNA transiently engineered anti-tumor CD8+ T cells. , 2019, , .		0